Reagentes e instrumentos para imunologia, biologia celular e biologia molecular.
 
> Vinorelbine (ditartrate) [125317-39-7]

Vinorelbine (ditartrate) [125317-39-7]

Imprimir Imprimir
Please log in

Referência HY-12053A-1ml

Tamanho : 10mM/1mL

Marca : MedChemExpress

Contactar o distribuidor local :


Telefone : +1 850 650 7790

Vinorelbine (ditartrate) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Vinorelbine ditartrate Chemical Structure

Vinorelbine ditartrate Chemical Structure

CAS No. : 125317-39-7

This product is a controlled substance and not for sale in your territory.

Based on 10 publication(s) in Google Scholar

Other Forms of Vinorelbine ditartrate:

  • Vinorelbine-d3 ditartrate In-stock
  • Vinorelbine Obtenir un devis
Description

Vinorelbine (ditartrate) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.

In Vitro

Vinorelbine (0.5-5 nM) ditartrate inhibits cell proliferation by 50% (IC50) at concentrations of 1.25 nM. At a concentration of 8 nM, no cells are in anaphase[1]. Vinorelbine ditartrate time-dependently induces the p53 and p21WAFI/CIP1 expression in androgen-dependent (AD) and- independent (AI) prostate cancer cell lines. Vinorelbine ditartrate stimulates reporter genes in a concentration-dependent manner[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Vinorelbine ditartrate Related Antibodies
Essai clinique
Masse moléculaire

1079.11

Formule

C53H66N4O20
CAS No.

125317-39-7
Appearance

Solid

Color

White to off-white

SMILES

CC[C@@]1(C=CCN2CC3)[C@@]2(11)[C@@]3(C(C=C([C@@](C4=C5C(C=CC=C6)=C6N4)(CC(C=C(CC)C7)(11)CN7C5)C(OC)=O)C(OC)=C8)=C8N9C)[C@]9(11)[C@](C(OC)=O)(O)[C@@H]1OC(C)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O
Structure Classification
  • Alkaloids
  • Alkaloid Dimers
Initial Source
  • Plants
  • Apocynaceae
  • Catharanthus roseus (L.) G. Don
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvant et solubilité
In Vitro: 

DMSO : 125 mg/mL (115.84 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 100 mg/mL (92.67 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.9267 mL 4.6334 mL 9.2669 mL
5 mM 0.1853 mL 0.9267 mL 1.8534 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Calculateur de molarité

  • Calculateur de dilution

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.08 mg/mL (1.93 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.08 mg/mL (1.93 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 50 mg/mL (46.33 mM); Clear solution; Need ultrasonic

  • Protocol 2

    Add each solvent one by one:  Saline

    Solubility: 20 mg/mL (18.53 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Pureté et documentation

Purity: 99.88%

COA (266 KB) LCMS (94 KB)

Instruction de manipulation (2659 KB)
Références

  • [1]. Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60(1):225-32.  [Content Brief]

    [2]. Liu XM, et al. Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer. 2003 Oct 20;89(8):1566-73.  [Content Brief]

    [3]. Poirier VJ, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004 Jul-Aug;18(4):536-9.  [Content Brief]

    [4]. Pierro JA, et al. Phase I clinical trial of vinorelbine in tumor-bearing cats. J Vet Intern Med. 2013 Jul-Aug;27(4):943-8.  [Content Brief]

Administration animale
[4]

As defined by the study, VRL1 is diluted in 0.9% NaCl to a concentration of 1.5 mg/mL, and given IV over 5 minutes. The intended treatment interval is 7 days for up to 4 treatments. After receiving 4 weekly doses, cats are eligible to continue VRL treatment every 2 weeks.

MCE n'a pas confirmé de manière indépendante l'exactitude de ces méthodes. Ils sont pour référence seulement.
Références

  • [1]. Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60(1):225-32.  [Content Brief]

    [2]. Liu XM, et al. Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer. 2003 Oct 20;89(8):1566-73.  [Content Brief]

    [3]. Poirier VJ, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004 Jul-Aug;18(4):536-9.  [Content Brief]

    [4]. Pierro JA, et al. Phase I clinical trial of vinorelbine in tumor-bearing cats. J Vet Intern Med. 2013 Jul-Aug;27(4):943-8.  [Content Brief]

  • [1]. Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60(1):225-32.

    [2]. Liu XM, et al. Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer. 2003 Oct 20;89(8):1566-73.

    [3]. Poirier VJ, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004 Jul-Aug;18(4):536-9.

    [4]. Pierro JA, et al. Phase I clinical trial of vinorelbine in tumor-bearing cats. J Vet Intern Med. 2013 Jul-Aug;27(4):943-8.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 0.9267 mL 4.6334 mL 9.2669 mL 23.1672 mL
5 mM 0.1853 mL 0.9267 mL 1.8534 mL 4.6334 mL
10 mM 0.0927 mL 0.4633 mL 0.9267 mL 2.3167 mL
15 mM 0.0618 mL 0.3089 mL 0.6178 mL 1.5445 mL
20 mM 0.0463 mL 0.2317 mL 0.4633 mL 1.1584 mL
25 mM 0.0371 mL 0.1853 mL 0.3707 mL 0.9267 mL
30 mM 0.0309 mL 0.1544 mL 0.3089 mL 0.7722 mL
40 mM 0.0232 mL 0.1158 mL 0.2317 mL 0.5792 mL
50 mM 0.0185 mL 0.0927 mL 0.1853 mL 0.4633 mL
60 mM 0.0154 mL 0.0772 mL 0.1544 mL 0.3861 mL
80 mM 0.0116 mL 0.0579 mL 0.1158 mL 0.2896 mL
DMSO 100 mM 0.0093 mL 0.0463 mL 0.0927 mL 0.2317 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Vinorelbine ditartrate Related Classifications

  • Cell Cycle/DNA Damage Cytoskeleton Autophagy
  • Microtubule/Tubulin Autophagy
Help & FAQs

Keywords:

Vinorelbine ditartrate125317-39-7KW-2307 Nor-5'-anhydrovinblastine ditartrateKW2307KW 2307Microtubule/TubulinAutophagyInhibitorinhibitorinhibit

Você também pode estar interessado nos seguintes produtos:



Referência
Descrição
Cond.
Price Bef. VAT